LWB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Ryoncil Commercial Traction And RevenueSustained commercial uptake with H1 revenue and FY guidance shows the company has moved from purely clinical to commercial execution. Durable payer coverage and center onboarding improve recurring revenue prospects and support scaling of sales infrastructure over the next 2–6 months.
Very High Gross MarginsA 93% gross margin indicates product economics are structurally strong, supporting future profitability as volume grows. High margins reduce the revenue needed to cover fixed operating costs and improve long-term cash conversion if commercial scale and reimbursement persist.
Strong Balance Sheet And Financing FlexibilityMaterial cash plus a nondilutive facility provide runway to support launches, file BLAs and fund confirmatory trials without immediate equity dilution. This structural financing flexibility lowers short-term funding risk and supports multi-program development over the next several quarters.
Bears Say
Revenue Concentration RiskDependence on a single product for nearly all revenue leaves the company exposed to uptake variability, reimbursement shifts, or clinical/regulatory setbacks. Sustained growth requires diversification from pipeline approvals or label expansions to reduce single-product exposure.
Negative Operating Cash Flow And Rising Operating CostsSignificant R&D and commercial investments are increasing cash burn despite improving revenue. Persistent negative operating cash flow necessitates continued funding or rapid margin conversion; otherwise runway and strategic optionality could be constrained within 2–6 months.
Manufacturing, CMC And Regulatory Execution RiskRegulatory filings and approvals hinge on validated manufacturing and potency assays. Any delays or scale-up issues can push BLA submissions or approvals, directly affecting product rollouts and revenue realization; this is a structural execution risk for pipeline commercialization.
Mesoblast Limited News
LWB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Currently, no data Available
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is CHF1.50B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -CHF0.025 earnings per share for the quarter, missing the consensus estimate of -CHF0.006 by -CHF0.019.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,298,748,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -CHF0.025 in its last earnings report, missing expectations of -CHF0.006. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in CH:LWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF2.01 (― Upside)
CHF2.01 (― Upside)
Blogger Sentiment
Bullish
CH:LWB Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
LWB Stock 12 Month Forecast
Average Price Target
―Cynata Therapeutics Limited
―
Living Cell Technologies
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―